Developer docs
API playgroundTry for free, no card

Search company profiles

Excellos

Full company profile

uuid0000nip

Namestring
Excellos
Legal namestring
EXCELLOS, Inc.
Websiteurl
excellos.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Excellos Labs is a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO) founded in 2021 as an independent spinout of the San Diego Blood Bank and headquartered in downtown San Diego. The company provides an integrated donor-to-dose manufacturing model serving pharmaceutical and biotechnology developers of adoptive cell therapies, including TIL Therapy, autologous and allogeneic CAR-T/NK Therapies, and TCR Therapy for cancer and autoimmune indications. Core operations span customized apheresis donor cell collection, cell isolation and enrichment, genetic modification, transduction, expansion, fill/finish, and cryopreservation under cGMP conditions across five ISO 7 cleanroom suites.

Short descriptiontext

Excellos Labs is a cell therapy CTDMO providing integrated donor-to-dose cGMP manufacturing services — from apheresis collection through cryopreservation — for pharmaceutical and biotech developers of adoptive cell therapies including CAR-T, TIL, and TCR therapies.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy CDMO, cGMP manufacturing, apheresis donor collection, cell isolation services, CAR-T manufacturing
Industry4 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Contract Development and Manufacturing (CDMO/CTDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services (CDMO)
TypeProfessional Services
Description

Provides continuum of services from donor recruitment to establishment of genetically modified working cell banks including apheresis donor cell collection, cell processing, cell isolation and enrichment, genetic modification, analysis, expansion, and cryopreservation. Services are contracted on a project basis with phase-appropriate engagement from pre-clinical through commercial stages.

excelloslabs.com
2Cell Therapy Products Catalog
TypeOne Time License
Description

Sells biological products including Leukapheresis-derived products, cord blood units, PBMCs, T Cells (alpha beta, gamma delta), NK Cells, CD34+ cells, and others. Products available as RUI and GMP materials, fresh or cryopreserved, with extensive characterization data.

excelloslabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom CDMO Services - Quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Contract manufacturing services tailored to customer requirements from pre-clinical through commercial stages. Pricing determined by project scope, cell type, manufacturing phase, and characterization requirements.

excelloslabs.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Excellos Labs operates as a cell therapy Contract Development and Manufacturing Organization (CTDMO) providing end-to-end services from donor collection through commercial cGMP manufacturing. The company offers a donor-to-dose model combining a consented, recallable donor pool with deep cell characterization, apheresis collection, cell isolation, transduction, expansion, cryopreservation, and QA/regulatory services under ISO 7 cleanroom conditions, alongside a product catalog of leukapheresis and cord blood-derived starting materials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reducing variabilities in clinical responses and increasing probability of success in trials through better starting material characterization
+1 more record
Product overview1 text field

Excellos Labs operates as a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO) with two integrated offerings: a product catalog of cell therapy starting materials and contract development manufacturing services. The product portfolio includes Leukopak, LRS Chambers, isolated cells from peripheral blood (PBMCs, T Cells, NK Cells, CD34+), isolated cells from cord blood, and cord blood units—available as research-use, RUI, or GMP-grade materials, fresh or cryopreserved. The services portfolio provides a continuum from donor recruitment through commercial GMP manufacturing, encompassing customized cell collections, cell isolation, process development, tech transfer, cGMP manufacturing, transduction, expansion, cryopreservation, storage, and stability testing. Both offerings share deep cell characterization capabilities including immune profiling, metabolic assessment, effector potential evaluation, HLA typing, and longitudinal donor data. The company operates as a fully integrated subsidiary of OrganaBio following the 2026 acquisition, spanning facilities in Miami and San Diego under a unified quality management system.

Product and service11 records
1Leukopak
CategoryCell Therapy Starting Materials
Description

Leukapheresis-derived products collected from consented, recallable donors, available fresh or cryopreserved, serving as starting material for cell therapy manufacturing.

2LRS Chambers
CategoryCell Therapy Starting Materials
Description

Products derived from Leukoreduction System (LRS) chambers, providing additional starting material options for cell therapy development.

3Isolated Cells from Peripheral Blood
CategoryCell Therapy Starting Materials
Description

Isolated cells including PBMCs, T Cells (alpha beta, gamma delta), NK Cells, and CD34+ cells derived from peripheral blood for immunotherapy research and manufacturing.

4Isolated Cells from Cord Blood
CategoryCell Therapy Starting Materials
Description

Isolated cells derived from cord blood units, providing an alternative starting material source for cell therapy manufacturing programs.

5Cord Blood Unit
CategoryCell Therapy Starting Materials
Description

Whole cord blood units available as starting material for cell therapy manufacturing and research applications.

6GMP Products
CategoryCell Therapy Starting Materials
Description

GMP-grade materials and cells manufactured under cGMP conditions in ISO 7 cleanrooms, available by custom order for clinical and commercial cell therapy programs.

7Customized Cell Collections
CategoryCDMO Services
Description

Custom apheresis donor cell collection services with access to a consented, recallable donor pool with rich diversity in ethnicity, sex, and age for clinical trial starting materials.

8Cell Isolation
CategoryCDMO Services
Description

Cell isolation and enrichment services including PBMC isolation, T cell isolation, NK cell isolation, and CD34+ cell selection for downstream cell therapy applications.

9Process Development and GMP Manufacturing
CategoryCDMO Services
Description

End-to-end cGMP manufacturing services including process development, optimization, scale-up, cell transduction, expansion, fill-finish, and cryopreservation in ISO 7 cleanroom suites.

10Quality Assurance and Regulatory
CategoryCDMO Services
Description

Comprehensive quality assurance including Quality by Design (QBD) and Manufacturing by Design (MBD) frameworks, with phase-appropriate regulatory compliance support for clinical and commercial programs.

11Cryopreservation and Storage
CategoryCDMO Services
Description

Cryopreservation, long-term storage, and stability testing services for cell therapy products, including third-party cryopreservation capabilities.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

OrganaBio acquired substantially all operating assets of Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization (CTDMO). Excellos Labs operates as a fully integrated subsidiary of OrganaBio, maintaining its name while combining complementary capabilities and expanding geographic coverage across Miami, San Diego, San Francisco, and Irvine facilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Strategic partnership and investment from Vitalant, a major nonprofit blood and biotherapies organization. Collaboration focuses on enhancing donor profiles, sourcing, testing, and laboratory services for cell therapy development and manufacturing. Vitalant provides funding and logistical support to accelerate new product launch and donor characterization, aiming to improve efficacy and reduce costs of cell therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is one of the largest global CDMOs offering cell and gene therapy manufacturing services across autologous and allogeneic platforms. Comparable to Excellos as a contract manufacturer serving pharma and biotech cell therapy developers, but at vastly greater scale, geographic reach, and with broader service breadth.

TypeBroad incumbent
Description

Catalent provides cell therapy development and manufacturing services including viral vector and cell processing for CAR-T and related modalities. Comparable as a CDMO serving the same pharma/biotech cell therapy developer base, but operating global commercial-scale GMP capacity versus Excellos' clinical-stage focus.

TypeDirect peer
Description

OrganaBio is a cell and tissue supplier and CTDMO focused on providing human-derived starting materials (PBMCs, bone marrow, cord blood) and cGMP manufacturing services. It is now Excellos' parent company post-2026 acquisition, with directly overlapping customer base and complementary capabilities in donor sourcing and cell processing.

TypeEmerging player
Description

Cellares is an emerging cell therapy manufacturing automation company developing closed-system, scalable platforms (Cell Shuttle) intended to industrialize cell therapy production. Comparable as a CTDMO/automation player addressing the same scaling and consistency challenges in autologous and allogeneic cell therapy manufacturing that Excellos targets.

TypeEmerging player
Description

RoslinCT is a cell and gene therapy CDMO with cGMP manufacturing for autologous and allogeneic cell therapies, including CAR-T and iPSC-derived products. Comparable as a specialized, Phase 1-to-commercial CTDMO serving the same biotech customer profile as Excellos, with overlapping modality focus.

TypeDirect peer
Description

Discovery Life Sciences provides human biospecimens, cell processing, and cGMP cell therapy manufacturing services. Comparable as a cell therapy CDMO with a donor-derived starting materials catalog alongside contract manufacturing — overlapping directly with Excellos' Leukopak and isolated cell product lines and CDMO services.

TypeEmerging player
Description

Kytopen develops Flowfect, a non-viral cell engineering platform for scalable manufacturing of cell therapies. Comparable as an emerging technology partner in the cell therapy manufacturing value chain and an active collaborator with Excellos, addressing the same customers and modality shift toward non-viral cell engineering.

TypeEmerging player
Description

Cellular Origins is an emerging cell therapy manufacturing automation company focused on scalable, closed-system production of cell therapies. Comparable as a CTDMO-adjacent technology player tackling manufacturing scale and cost challenges for autologous and allogeneic cell therapy developers — the same customer base Excellos serves.

TypeEmerging player
Description

BioBridge Global operates GenCure and other subsidiaries providing cell and tissue services including apheresis, cell processing, and biomanufacturing. Comparable as a nonprofit-affiliated supplier of donor-derived starting materials and cell therapy services, with a similar institutional lineage to Excellos' San Diego Blood Bank roots.

TypeOthers
Description

IsoPlexis (now Standard BioTools' cell biology unit) provides single-cell proteomics tools used to characterize cell therapy products including CAR-T cells. Comparable as an enabling technology provider in the cell therapy characterization workflow that complements Excellos' Deep Cell Characterization Platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Excellos

Cell Therapy Contract Development and Manufacturing (CDMO/CTDMO)excellos.com

Excellos Labs is a cell therapy CTDMO providing integrated donor-to-dose cGMP manufacturing services — from apheresis collection through cryopreservation — for pharmaceutical and biotech developers of adoptive cell therapies including CAR-T, TIL, and TCR therapies.

What Excellos does

Excellos Labs is a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO) founded in 2021 as an independent spinout of the San Diego Blood Bank and headquartered in downtown San Diego. The company provides an integrated donor-to-dose manufacturing model serving pharmaceutical and biotechnology developers of adoptive cell therapies, including TIL Therapy, autologous and allogeneic CAR-T/NK Therapies, and TCR Therapy for cancer and autoimmune indications. Core operations span customized apheresis donor cell collection, cell isolation and enrichment, genetic modification, transduction, expansion, fill/finish, and cryopreservation under cGMP conditions across five ISO 7 cleanroom suites.

Excellos firmographics

Firmographics
Name
Excellos
Legal name
EXCELLOS, Inc.
Website
https://excellos.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
11–50 employees
Short description
Excellos Labs is a cell therapy CTDMO providing integrated donor-to-dose cGMP manufacturing services — from apheresis collection through cryopreservation — for pharmaceutical and biotech developers of adoptive cell therapies including CAR-T, TIL, and TCR therapies.
Ownership category
akta.pro rank

Excellos industry classification

Industry
Product category
Cell Therapy Contract Development and Manufacturing (CDMO/CTDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy CDMO
  • CGMP manufacturing
  • Apheresis donor collection
  • Cell isolation services
  • CAR-T manufacturing

Where Excellos is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Excellos business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services (CDMO): Provides continuum of services from donor recruitment to establishment of genetically modified working cell banks including apheresis donor cell collection, cell processing, cell isolation and enrichment, genetic modification, analysis, expansion, and cryopreservation. Services are contracted on a project basis with phase-appropriate engagement from pre-clinical through commercial stages.
  2. Cell Therapy Products Catalog: Sells biological products including Leukapheresis-derived products, cord blood units, PBMCs, T Cells (alpha beta, gamma delta), NK Cells, CD34+ cells, and others. Products available as RUI and GMP materials, fresh or cryopreserved, with extensive characterization data.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CDMO Services - Quote-based pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Excellos product offering

Product offering

Core offering

Excellos Labs operates as a cell therapy Contract Development and Manufacturing Organization (CTDMO) providing end-to-end services from donor collection through commercial cGMP manufacturing. The company offers a donor-to-dose model combining a consented, recallable donor pool with deep cell characterization, apheresis collection, cell isolation, transduction, expansion, cryopreservation, and QA/regulatory services under ISO 7 cleanroom conditions, alongside a product catalog of leukapheresis and cord blood-derived starting materials.

Product overview

Excellos Labs operates as a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO) with two integrated offerings: a product catalog of cell therapy starting materials and contract development manufacturing services. The product portfolio includes Leukopak, LRS Chambers, isolated cells from peripheral blood (PBMCs, T Cells, NK Cells, CD34+), isolated cells from cord blood, and cord blood units—available as research-use, RUI, or GMP-grade materials, fresh or cryopreserved. The services portfolio provides a continuum from donor recruitment through commercial GMP manufacturing, encompassing customized cell collections, cell isolation, process development, tech transfer, cGMP manufacturing, transduction, expansion, cryopreservation, storage, and stability testing. Both offerings share deep cell characterization capabilities including immune profiling, metabolic assessment, effector potential evaluation, HLA typing, and longitudinal donor data. The company operates as a fully integrated subsidiary of OrganaBio following the 2026 acquisition, spanning facilities in Miami and San Diego under a unified quality management system.

Differentiator

Problem solved

Functional benefit

Products and services

  • Leukopak Leukapheresis-derived products collected from consented, recallable donors, available fresh or cryopreserved, serving as starting material for cell therapy manufacturing.
  • LRS Chambers Products derived from Leukoreduction System (LRS) chambers, providing additional starting material options for cell therapy development.
  • Isolated Cells from Peripheral Blood Isolated cells including PBMCs, T Cells (alpha beta, gamma delta), NK Cells, and CD34+ cells derived from peripheral blood for immunotherapy research and manufacturing.
  • Isolated Cells from Cord Blood Isolated cells derived from cord blood units, providing an alternative starting material source for cell therapy manufacturing programs.
  • Cord Blood Unit Whole cord blood units available as starting material for cell therapy manufacturing and research applications.
  • GMP Products GMP-grade materials and cells manufactured under cGMP conditions in ISO 7 cleanrooms, available by custom order for clinical and commercial cell therapy programs.
  • Customized Cell Collections Custom apheresis donor cell collection services with access to a consented, recallable donor pool with rich diversity in ethnicity, sex, and age for clinical trial starting materials.
  • Cell Isolation Cell isolation and enrichment services including PBMC isolation, T cell isolation, NK cell isolation, and CD34+ cell selection for downstream cell therapy applications.
  • Process Development and GMP Manufacturing End-to-end cGMP manufacturing services including process development, optimization, scale-up, cell transduction, expansion, fill-finish, and cryopreservation in ISO 7 cleanroom suites.
  • Quality Assurance and Regulatory Comprehensive quality assurance including Quality by Design (QBD) and Manufacturing by Design (MBD) frameworks, with phase-appropriate regulatory compliance support for clinical and commercial programs.
  • Cryopreservation and Storage Cryopreservation, long-term storage, and stability testing services for cell therapy products, including third-party cryopreservation capabilities.

Quantifiable outcome

  • Reducing variabilities in clinical responses and increasing probability of success in trials through better starting material characterization
  • +1 more outcomes

Companies that use Excellos

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Excellos technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Excellos partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • OrganaBiocoreStrategic or Co-development Partner · 13 May 2026OrganaBio acquired substantially all operating assets of Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization (CTDMO). Excellos Labs operates as a fully integrated subsidiary of OrganaBio, maintaining its name while combining complementary capabilities and expanding geographic coverage across Miami, San Diego, San Francisco, and Irvine facilities.
  • VitalantcoreStrategic or Co-development Partner · 17 January 2024Strategic partnership and investment from Vitalant, a major nonprofit blood and biotherapies organization. Collaboration focuses on enhancing donor profiles, sourcing, testing, and laboratory services for cell therapy development and manufacturing. Vitalant provides funding and logistical support to accelerate new product launch and donor characterization, aiming to improve efficacy and reduce costs of cell therapies.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Excellos competitors and assessment

Company assessment

Broad incumbents

  • Lonza Cell & Gene Therapies: Lonza is one of the largest global CDMOs offering cell and gene therapy manufacturing services across autologous and allogeneic platforms. Comparable to Excellos as a contract manufacturer serving pharma and biotech cell therapy developers, but at vastly greater scale, geographic reach, and with broader service breadth.
  • Catalent Cell Therapy Services: Catalent provides cell therapy development and manufacturing services including viral vector and cell processing for CAR-T and related modalities. Comparable as a CDMO serving the same pharma/biotech cell therapy developer base, but operating global commercial-scale GMP capacity versus Excellos' clinical-stage focus.

Direct peers

  • OrganaBio: OrganaBio is a cell and tissue supplier and CTDMO focused on providing human-derived starting materials (PBMCs, bone marrow, cord blood) and cGMP manufacturing services. It is now Excellos' parent company post-2026 acquisition, with directly overlapping customer base and complementary capabilities in donor sourcing and cell processing.
  • Discovery Life Sciences: Discovery Life Sciences provides human biospecimens, cell processing, and cGMP cell therapy manufacturing services. Comparable as a cell therapy CDMO with a donor-derived starting materials catalog alongside contract manufacturing — overlapping directly with Excellos' Leukopak and isolated cell product lines and CDMO services.

Emerging players

  • Cellares: Cellares is an emerging cell therapy manufacturing automation company developing closed-system, scalable platforms (Cell Shuttle) intended to industrialize cell therapy production. Comparable as a CTDMO/automation player addressing the same scaling and consistency challenges in autologous and allogeneic cell therapy manufacturing that Excellos targets.
  • RoslinCT: RoslinCT is a cell and gene therapy CDMO with cGMP manufacturing for autologous and allogeneic cell therapies, including CAR-T and iPSC-derived products. Comparable as a specialized, Phase 1-to-commercial CTDMO serving the same biotech customer profile as Excellos, with overlapping modality focus.
  • Kytopen: Kytopen develops Flowfect, a non-viral cell engineering platform for scalable manufacturing of cell therapies. Comparable as an emerging technology partner in the cell therapy manufacturing value chain and an active collaborator with Excellos, addressing the same customers and modality shift toward non-viral cell engineering.
  • Cellular Origins: Cellular Origins is an emerging cell therapy manufacturing automation company focused on scalable, closed-system production of cell therapies. Comparable as a CTDMO-adjacent technology player tackling manufacturing scale and cost challenges for autologous and allogeneic cell therapy developers — the same customer base Excellos serves.
  • BioBridge Global: BioBridge Global operates GenCure and other subsidiaries providing cell and tissue services including apheresis, cell processing, and biomanufacturing. Comparable as a nonprofit-affiliated supplier of donor-derived starting materials and cell therapy services, with a similar institutional lineage to Excellos' San Diego Blood Bank roots.

Others

  • IsoPlexis: IsoPlexis (now Standard BioTools' cell biology unit) provides single-cell proteomics tools used to characterize cell therapy products including CAR-T cells. Comparable as an enabling technology provider in the cell therapy characterization workflow that complements Excellos' Deep Cell Characterization Platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Excellos social profiles

Digital presence

Excellos compliance and trust

Trust signal

Compliance1 record

Excellos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Excellos leadership team

Management profile

Number of profiles

Profiles2 records

Excellos funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Excellos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Excellos

What does Excellos do?

Excellos Labs operates as a cell therapy Contract Development and Manufacturing Organization (CTDMO) providing end-to-end services from donor collection through commercial cGMP manufacturing. The company offers a donor-to-dose model combining a consented, recallable donor pool with deep cell characterization, apheresis collection, cell isolation, transduction, expansion, cryopreservation, and QA/regulatory services under ISO 7 cleanroom conditions, alongside a product catalog of leukapheresis and cord blood-derived starting materials.

Is Excellos a public or private company?

Excellos is a private company. It is classified as corporate owned and is currently acquired.

When was Excellos founded?

Excellos was founded in 2021. It employs 11 to 50 people.

Where is Excellos based?

Excellos is headquartered in San Diego, United States, in the North America region.

How does Excellos make money?

Two revenue lines are on record. Contract Development and Manufacturing Services (CDMO) is the primary driver. The others are cell Therapy Products Catalog.

Who are Excellos's main competitors?

Broad incumbents on record are Lonza Cell & Gene Therapies and Catalent Cell Therapy Services. Direct peers are OrganaBio and Discovery Life Sciences. Emerging players are Cellares, RoslinCT, Kytopen, Cellular Origins and BioBridge Global. IsoPlexis is listed as an others.

Does Excellos have an API?

No public API is recorded for Excellos.

What industry is Excellos in?

Excellos's product category is Cell Therapy Contract Development and Manufacturing (CDMO/CTDMO). Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SdbnLocal PBMC Isolation Enables Four-Hour Processing in San Diego – San Diego Biotechnology NetworkOrganaBio opened a new PBMC processing and cryopreservation laboratory at Excellos Labs in San Diego, enabling isolation and cryopreservation of peripheral blood mononuclear cells within three to four hours of collection. The facility, located at a company OrganaBio acquired in May, removes the bottleneck of shipping live material across the country for cell and gene therapy developers. The CEO emphasized that the quality locked in at cryopreservation directly determines the quality developers receive back months later.Pulse 2.0OrganaBio Acquires Excellos Operating Assets To Build Coast-To-Coast Cell Therapy Manufacturing PlatformOrganaBio announced the acquisition of all Excellos operating assets, establishing a bicoastal cell therapy contract testing, development, and manufacturing organization. The newly formed Excellos Labs subsidiary will oversee San Diego operations, with the combined platform now spanning facilities in Miami, San Francisco, Irvine, and San Diego, integrating capabilities across manufacturing, PBMC isolation, cryopreservation, and cell processing services. The transaction adds five ISO 7 cGMP cleanroom suites to OrganaBio's existing infrastructure, supporting both autologous and allogeneic cell therapy programs focused on cancer and autoimmune indications, with full integration expected over the next 12 months.BioSpaceOrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing OrganizationOrganaBio acquired Excellos' operating assets to create a bicoastal cell therapy CDMO, with Excellos Labs handling San Diego operations. The combined platform spans multiple U.S. facilities, including Miami, San Francisco, Irvine, and San Diego, offering cGMP manufacturing, PBMC isolation, and cryopreservation. Full integration is expected over 12 months.Financial PostOrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing OrganizationOrganaBio, LLC, a Miami-based manufacturer of GMP cells and blood products, has acquired substantially all operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization (CTDMO). The newly combined entity spans facilities across Miami, San Diego, San Francisco, and Irvine, offering GMP manufacturing, PBMC isolation, cryopreservation, and cell therapy services under a single quality framework. The acquisition positions OrganaBio to address supply chain risks for cell therapy developers by providing geographic and infrastructure redundancy while retaining the core Excellos team to ensure uninterrupted customer programs.citybizOrganaBio Acquires Excellos Assets to Build Bicoastal Cell Therapy Manufacturing NetworkMiami-based OrganaBio has acquired substantially all operating assets of San Diego-based Excellos, creating a coast-to-coast contract development and manufacturing platform for the cell therapy sector. The combined organization now operates facilities in Miami, San Diego, San Francisco, and Irvine, California, with the acquisition designed to address supply chain and operational risks that developers face when relying on single manufacturing sites. Full operational integration is expected over the next year, with the merged customer base including many of the world's largest pharmaceutical companies and biotechnology firms developing cancer and autoimmune therapies.Business Wire BlogOrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing OrganizationOrganaBio, LLC has acquired substantially all operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization, with newly formed subsidiary Excellos Labs handling San Diego operations. The acquisition combines complementary capabilities and expands geographic coverage across multiple U.S. facilities, with OrganaBio's Miami headquarters anchoring East Coast operations and Excellos' downtown San Diego facility adding West Coast capacity. The combined entity now offers manufacturing redundancy and addresses supply chain risks for cell therapy developers, supporting a customer base that includes top 20 global pharmaceutical companies and biotechnology developers.The Pharma LetterOrganaBio acquires Excellos assets, expanding US operationsOrganaBio acquired substantially all of San Diego-based Excellos' operating assets to create a bicoastal cell therapy CDMO. The new Excellos Labs subsidiary will handle San Diego operations, combining complementary capabilities and expanding geographic coverage.InsightsCollaboration in action: decentralized manufacturing to expand patient access in cell therapyDecentralized manufacturing is being promoted as a transformative strategy to enhance access to cell therapies, facilitated by organizations like Lonza, Galapagos, Blood Centers of America, and Excellos. The initiative involves integrating community-based apheresis networks and automated manufacturing platforms to deliver therapies more efficiently and at scale. This collaboration aims to reduce barriers to production and improve patient access to these therapies.MorningstarExcellos, Lonza, and Akadeum Life Sciences Unite to Advance Cell Therapy Manufacturing Through Enhanced Starting Material QualityExcellos, Lonza, and Akadeum Life Sciences announced a project to advance cell therapy manufacturing by improving starting material quality. The collaboration combines donor characterization, automated manufacturing, and cell separation, with a symposium on August 12 and a webinar on August 21. The companies plan to explore deeper technical integration and data-sharing.PR NewswireExcellos, Lonza, and Akadeum Life Sciences Unite to Advance Cell Therapy Manufacturing Through Enhanced Starting Material QualityExcellos, Lonza, and Akadeum announced a project to advance cell therapy manufacturing by improving starting material quality. The collaboration combines donor characterization, automated manufacturing, and cell separation, with events planned for August 12 and 21. The companies aim to explore technical integration and data-sharing over the coming months.